Online Program

Return to main conference page
Tuesday, September 24
Tue, Sep 24, 2:45 PM - 4:00 PM
Thurgood Marshall East
Statistical Considerations in the Evaluation of Vaccine Efficacy and Effectiveness

Hybrid Clinical Trials to Generate Real-World Evidence: Design Considerations from a Sponsor Perspective (300985)

*Judy Pan, Sanofi Pasteur 
Ming Zhu, Sanofi Pasteur 

Keywords: vaccine, hybrid design

With the advancement of technologies and availability of RWD, there is increasing interest from the pharmaceutical industry and regulators alike to utilize such data. Hybrid design preserves the benefit of randomization, provides real-world outcome data and potentially accelerates product development and lowers the costs of data collection and patient follow-up. In this presentation, we focus on design considerations for hybrid trials to support regulatory decisions from a sponsor’s perspective. We emphasize vaccine development where such hybrid designs are particularly useful given the low incidence rates of some vaccine preventable clinical outcomes. We propose program strategies on how such hybrid designs may be integrated into a clinical development plan. Major challenges are discussed and recommendations are provided.